JMJD8

Across TCGA pan-cancer cohorts, JMJD8 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated JMJD8 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher JMJD8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated JMJD8 expression acts as an unfavorable survival marker.

LIHC, KIRC, and ACC are the cancer types where JMJD8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.077	0.527	.002	15	view →
KIRC	OS	Median	All	0.144	0.655	.029	12	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
SKCM	DFS	Median	All	0.192	0.757	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

JMJD8–LIHC (DFS)

Open the LIHC breakdown →